C5G.F Orexo AB (publ)

Healthcare Pharmaceuticals Frankfurt Exchange
0.0815 EUR
Close of Nov 12, 2026
0.0278 3.38
Market cap
EUR 4.57M
P/E
-
P/B
0.17x
ROE
-248.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is C5G.F undervalued?

Graham number

The Graham number of Orexo AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orexo AB (publ) fundamental analysis

No fundamental analysis for Orexo AB (publ) yet.

Orexo AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orexo AB (publ)

Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is deve…

Full company profile